Global Alzheimer’s Platform Foundation Collaborates on First-Ever Performance Recommendations for Blood-Based Biomarker Tests

Washington D.C., June. 14, 2024- Global Alzheimer’s Platform Foundation® (GAP) proudly collaborated with The Global CEO Initiative on Alzheimer’s Disease (CEOi) to release the peer-reviewed publication of “Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease,” in Nature Reviews Neurology.

Alzheimer’s blood tests have the potential to revolutionize early and accurate diagnoses for patients with cognitive impairment. However, the performance of these tests can vary, raising the question of the minimum accuracy required for a test to be clinically useful. To address this, CEOi convened a diverse group of expert stakeholders, the Blood-based Biomarker (BBM) Workgroup, marking the first expert consensus on a unified framework for BBM tests in clinical practice.

John Dwyer, President of the Global Alzheimer’s Platform Foundation and co-author of the paper stated, “In these unprecedented times, to have multiple therapies coming through the approval and reimbursement process in the USA, it heightens the need to validate biomarkers to help facilitate the treatment of patients and to expedite future clinical trial work. That was the underlying thesis for the endeavor, and it was done with great discipline and alacrity. I am honored to be a contributor to the paper “Acceptable performance of blood biomarker tests of amyloid pathology” in Nature Reviews Neurology, a peer-reviewed paper that will catalyze more accurate diagnosis of AD and more access to new therapies.”

GAP is proud to be part of the solution and will continue as we launch our Bio-Hermes-002 study. Discover more about the newly published recommendations on advancing Alzheimer’s diagnostics for all and visit here.

To top